FINWIRES · TerminalLIVE
FINWIRES

JL Mag Rare-Earth Terminates AU$7 Million Hastings Equity Subscription

By

JL Mag Rare-Earth (HKG:6680, SHE:300748) terminated plans to subscribe for shares in Australian rare-earth company Hastings Technology Metals (ASX:HAS) after conditions precedent to the deal were not fulfilled.

The subscription involved 19.7 million Hastings shares at AU$0.36 each, for a total consideration of about AU$7.1 million, according to an Aug. 7 filing with the Hong Kong bourse.

JL Mag said it had not made any payment to Hastings and the subscription terms had not taken effect.

The termination is not expected to have a material impact on the company's operations, it said.

Related Articles

Asia

Aspial Lifestyle's H1 Attributable Profit Surges 88%

Aspial Lifestyle's (SGX:5UF) recorded an 88% rise in attributable profit in the first half of 2026 to SG$52.4 million from SG$27.9 million a year prior.Earnings per share stood at SG$0.0277, up from SG$0.015 previously, according to a Friday filing with the Singapore bourse.Revenue jumped 26% to SG$464.2 million from SG$367.2 million in the year-ago period.

SGX:5UF
Asia

Sino Biopharma Unit Gets China Nod to Market Lung Cancer Drug

Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's Benmelstobart Injection obtained marketing approval from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approval is for use of the drug in combination with chemotherapy and sequentially followed by Anlotinib Hydrochloride Capsules for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.

HKG:1177
Asia

Lygend Resources Gets CSRC Nod for China Listed-Share IPO

Lygend Resources & Technology (HKG:2245) obtained approval for its registration application related to its China listed-share initial public offering from the China Securities Regulatory Commission (CSRC).The share offering is subject to various conditions, including certain final regulatory approvals, according to a Friday Hong Kong bourse filing.

HKG:2245